Drug Stocks Prey for Insiders as Industry Resists Change Bloomberg At a time when more than one in five U.S. insider-trading cases involve health-care stocks, the industry's companies say their policies designed to prevent abuse are sufficient -- or they refuse to publicly discuss the issue at all. Since 2007, 97 ... |
